Cargando…

Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies

Cell dose is a critical determinant of outcomes in unrelated cord blood (CB) transplantation. We investigated a strategy in which CB units should contain at least 2 × 10(7) total nucleated cells/kg of recipient weight, otherwise a second unit had to be added. We report the results of a study that wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lekakis, L, Giralt, S, Couriel, D, Shpall, E J, Hosing, C, Khouri, I F, Anderlini, P, Korbling, M, Martin, T, Champlin, R E, de Lima, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2006
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091659/ https://www.ncbi.nlm.nih.gov/pubmed/16892072 http://dx.doi.org/10.1038/sj.bmt.1705467

Ejemplares similares

A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin’s lymphomas
por: Hosing, Chitra, et al.
Publicado: (2010)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies
por: Singh, Harjeet, et al.
Publicado: (2022)

Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients
por: Sheshadri, Ajay, et al.
Publicado: (2020)

Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies
por: Li, Hua, et al.
Publicado: (2021)

Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases
por: Zeng, Cong, et al.
Publicado: (2022)

Phase II study of intrabone single unit cord blood transplantation for hematological malignancies
por: Murata, Makoto, et al.
Publicado: (2017)

The incidence, risk factors and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study
por: Ge, Jing, et al.
Publicado: (2018)

Cord Blood Maternal Microchimerism Following Unrelated Cord Blood Transplantation
por: Kanaan, Sami B., et al.
Publicado: (2020)

A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation
por: Lee, Myung-Won, et al.
Publicado: (2020)

Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation
por: Saliba, Rima M., et al.
Publicado: (2020)

Recipient ADAMTS13 Single-Nucleotide Polymorphism Predicts Relapse after Unrelated Bone Marrow Transplantation for Hematologic Malignancy
por: Nomoto, Haruka, et al.
Publicado: (2019)

Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type
por: Mehta, Rohtesh S., et al.
Publicado: (2023)

Infectious Complications After Umbilical Cord Blood Transplantation for Hematological Malignancy
por: Linder, Kathleen A, et al.
Publicado: (2019)

Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation
por: Cao, Kai, et al.
Publicado: (2018)

Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
por: Cheng, Yee Chung, et al.
Publicado: (2013)

Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
por: Mehta, Rohtesh S., et al.
Publicado: (2021)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study
por: Popat, Uday R., et al.
Publicado: (2022)

Risk Factors and Options to Improve Engraftment in Unrelated Cord Blood Transplantation
por: Petropoulou, Anna D., et al.
Publicado: (2011)

Donor-derived 47, XXY in an unrelated cord blood transplant recipient
por: Kawaguchi, Kuniki, et al.
Publicado: (2014)

Outcomes of patients with hematological malignancies who undergo unrelated donor hematopoietic stem cell transplantation with ATG-Fresenius versus ATG-Genzyme
por: Wang, Lu, et al.
Publicado: (2023)

Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children
por: Benadiba, Joy, et al.
Publicado: (2018)

Salvaged single-unit cord blood transplantation for 26 patients with hematologic malignancies not in remission
por: Yao, W., et al.
Publicado: (2015)

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement
por: Akin, Serkan, et al.
Publicado: (2022)

Pediatric cholecystectomy for symptomatic gallstones unrelated to hematologic disorder
por: Suh, Sang Gyun, et al.
Publicado: (2016)

Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors
por: Montoro, Juan, et al.
Publicado: (2016)

Unrelated Donor Cord Blood Transplantation in Children: Lessons Learned Over 3 Decades
por: Kurtzberg, Joanne, et al.
Publicado: (2023)

Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia
por: Sheikh, Irtiza N., et al.
Publicado: (2022)

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
por: Wieduwilt, Matthew J., et al.
Publicado: (2022)

Hematologic malignancies and Li–Fraumeni syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2019)

Romidepsin targets multiple survival signaling pathways in malignant T cells
por: Valdez, B C, et al.
Publicado: (2015)

Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Bashir, Qaiser, et al.
Publicado: (2022)

Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials
por: Mehta, Rohtesh S., et al.
Publicado: (2015)

1542. Infectious Complications in Patients Following Umbilical Cord Blood Transplant (UCBT) for Hematologic Malignancy
por: Linder, Kathleen A, et al.
Publicado: (2018)

Prolonged Varicella-Zoster Virus Reinfection in an Adult After Unrelated Cord Blood Transplantation
por: Oka, Masahiro, et al.
Publicado: (2012)

Unrelated umbilical cord blood transplantation for children with hereditary leukodystrophy: A retrospective study
por: Wang, Ping, et al.
Publicado: (2022)

Pediatric Cholecystectomy: Clinical Significance of Cases Unrelated to Hematologic Disorders
por: Kim, Hae-Young, et al.
Publicado: (2015)

Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation
por: Geller, RB, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_f7udok7mtdlmevdobbjvs57ro6